Cash Flow Statement (Annual)

HCOM / Hawaiian Telcom Holdco, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss - - - - 1,100 1,106 -107,241
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 63,806 70,908 77,301 78,014 87,879 89,916 88,424
    Amortization Of Financing Costs - - 1,813 1,855 1,922 2,068 1,442
    Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash - - - - - - -
    Provision For Doubtful Accounts 2,940 716 3,455 3,590 3,648 4,031 3,797
    Share Based Compensation 2,135 1,872 2,736 4,174 1,584 2,303 2,827
    Deferred Income Tax Expense Benefit - -90,827 9,617 6,851 1,958 1,332 88,628
    Increase Decrease In Operating Capital
      Increase Decrease In Receivables 2,930 724 3,409 1,731 3,722 4,672 2,649
      Increase Decrease In Inventories -240 3,161 4,587 386 -838 -409 -1,280
      Increase Decrease In Prepaid Deferred Expense And Other Assets -4,039 1,109 -456 504 -9 153 -95
      Increase Decrease In Accounts Payable And Accrued Liabilities -6,058 3,255 -6,518 3,882 -9,973 3,935 -1,059
      Increase Decrease In Customer Advances And Deposits -276 424 138 -1,436 8,565 -1,038 20,377
      Increase Decrease In Other Operating Liabilities 1,421 269 812 -296 -759 -344 -653
    Increase Decrease In Other Operating Capital Net 990 -1,676 -2,582 -2,224 -1,181 702 -336
  Net Cash Provided By Used In Operating Activities - - - - 90,596 90,088 98,710
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 77,992 77,713 86,290 96,706 99,034 97,841 95,256
  Net Cash Provided By Used In Investing Activities - - - - -98,229 -97,841 -95,256
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Long Term Debt - 295,500 298,500 - - - 330,000
  Repayments Of Long Term Capital Lease Obligations 582 582 542 3,179 4,217 3,341 3,961
  Repayments Of Long Term Debt - 306,750 303,083 3,000 3,000 3,000 305,263
  Payments Of Debt Restructuring Costs 253 - - - - - -
  Payments Related To Tax Withholding For Share Based Compensation 25 258 806 1,520 948 364 495
  Net Cash Provided By Used In Financing Activities - - - - 1,335 -5,238 16,409
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - -6,298 -12,991 19,863
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - 21,146 41,009

Peers - Communications Services, Not Elsewhere Classified (4899)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 420031106